J T Chambers
Overview
Explore the profile of J T Chambers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
527
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
PRICE F, Chambers S, Carcangiu M, Kohorn E, Schwartz P, Chambers J
Cancer
. 1998 May;
82(9):1720-5.
PMID: 9576294
Background: Although CA 125 level correlates with response to therapy in patients with serous carcinoma of the ovary, the utility of CA 125 in patients with high risk or metastatic...
12.
Carcangiu M, Tan L, Chambers J
Am J Surg Pathol
. 1997 Dec;
21(12):1507-14.
PMID: 9414196
Although in endometrioid type endometrial carcinoma depth of invasion is a powerful predictor of extrauterine disease and survival, in serous carcinoma its importance is unclear. Recurrences and death in patients...
13.
Chambers S, Chambers J, Davis C, Kohorn E, Schwartz P, Lorber M, et al.
J Clin Oncol
. 1997 May;
15(5):1945-52.
PMID: 9164206
Purpose: The feasibility and pharmacokinetics of cyclosporine (CsA) delivered intraperitoneally (IP) have not been previously explored. We performed a pharmacokinetic study of IP CsA followed by a phase I dose-escalation...
14.
Naftolin F, Rutherford T, Chambers J, Carcangiu M
J Soc Gynecol Investig
. 1997 Mar;
4(2):57.
PMID: 9101461
No abstract available.
15.
Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients
Chambers S, Davis C, Chambers J, Schwartz P, Lorber M, Hschumacher R
Clin Cancer Res
. 1996 Oct;
2(10):1699-704.
PMID: 9816119
Our objective was to determine the maximum tolerated dose of cyclosporin A (CsA) delivered as a loading dose (LD) and continuous i.v. infusion (CI) in combination with carboplatin in patients...
16.
Chambers S, Davis C, Schwartz P, Kohorn E, Chambers J
Clin Cancer Res
. 1996 Oct;
2(10):1693-7.
PMID: 9816118
Our objective was to assess the activity of cyclosporin A (CsA) used as a chemomodulator of carboplatin in refractory ovarian and fallopian tube cancer patients. Fifty-one patients (47 epithelial ovarian,...
17.
Cass I, Resnik E, Chambers J, Chambers S, Carcangiu M, Kohorn E, et al.
Gynecol Oncol
. 1996 Jun;
61(3):309-14.
PMID: 8641607
Eleven patients with ovarian (9) or fallopian tube (2) mixed müllerian tumors who underwent primary surgery at Yale New Haven Medical Center between 1986 and 1994 were treated with etoposide,...
18.
Zreik T, Chambers J, Chambers S
Obstet Gynecol
. 1996 May;
87(5 Pt 1):741-6.
PMID: 8677078
Objective: To evaluate the effect of resection of central disease when the parametria are involved by tumor in high-risk stage I cervical cancer patients. Methods: Thirty-two patients with high-risk stage...
19.
Fishman D, Roberts K, Chambers J, Kohorn E, Schwartz P, Chambers S
Gynecol Oncol
. 1996 May;
61(2):189-96.
PMID: 8626131
From 1975 to 1992, 54 patients with clinical Stage I and II endometrioid carcinoma of the endometrium, representing 3.5% of all such patients, were deemed medically inoperable and exclusively received...
20.
Chambers J, Chambers S, Kohorn E, Carcangiu M, Schwartz P
Gynecol Oncol
. 1996 Mar;
60(3):438-42.
PMID: 8774654
This study was designed to evaluate the efficacy of intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide in patients with uterine papillary serous carcinoma. Sixteen patients with uterine papillary serous carcinoma...